Nutriband Inc (NTRB) - Total Assets
Based on the latest financial reports, Nutriband Inc (NTRB) holds total assets worth $7.55 Million USD as of January 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Nutriband Inc (NTRB) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Nutriband Inc - Total Assets Trend (2016–2026)
This chart illustrates how Nutriband Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Nutriband Inc for net asset value and shareholders' equity analysis.
Nutriband Inc - Asset Composition Analysis
Current Asset Composition (January 2026)
Nutriband Inc's total assets of $7.55 Million consist of 66.1% current assets and 33.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.6% |
| Accounts Receivable | $118.40K | 1.6% |
| Inventory | $117.99K | 1.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $200.43K | 2.7% |
| Goodwill | $1.72 Million | 22.8% |
Asset Composition Trend (2016–2026)
This chart illustrates how Nutriband Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NTRB market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nutriband Inc's current assets represent 66.1% of total assets in 2026, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 60.6% of total assets in 2026, up from 30.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 22.8% of total assets.
Nutriband Inc Competitors by Total Assets
Key competitors of Nutriband Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Nutriband Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.36 | 4.88 | 0.37 |
| Quick Ratio | 6.21 | 4.66 | 0.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.20 Million | $3.81 Million | $-1.59 Million |
Nutriband Inc - Advanced Valuation Insights
This section examines the relationship between Nutriband Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.83 |
| Latest Market Cap to Assets Ratio | 4.59 |
| Asset Growth Rate (YoY) | 1.0% |
| Total Assets | $7.55 Million |
| Market Capitalization | $34.64 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nutriband Inc's assets at a significant premium (4.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Nutriband Inc's assets grew by 1.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Nutriband Inc (2016–2026)
The table below shows the annual total assets of Nutriband Inc from 2016 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-01-31 | $7.55 Million | +1.04% |
| 2025-01-31 | $7.47 Million | -0.63% |
| 2024-01-31 | $7.52 Million | -20.51% |
| 2023-01-31 | $9.46 Million | -25.77% |
| 2022-01-31 | $12.74 Million | +28.33% |
| 2021-01-31 | $9.93 Million | +351.71% |
| 2020-01-31 | $2.20 Million | -21.72% |
| 2019-01-31 | $2.81 Million | +1602.63% |
| 2018-01-31 | $164.90K | +337.08% |
| 2017-01-31 | $37.73K | +11332.42% |
| 2016-01-31 | $330.00 | -- |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more